Full Alliance Group Inc FAGI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FAGI is a good fit for your portfolio.
News
-
Full Alliance Group, Inc. Announces Craig Lane as President of its wholly owned subsidiary DYNAMAXX Health, Inc. (OTC: FAGI)
-
Dynamaxx Revitalizes its Product Portfolio, Launches Nine Enhanced and Newly Formulated Offerings: Full Alliance Group (OTC: "FAGI")
-
Millionaires Club Founder and Top 100 Global MLM Earner Edgar Mojica Joins DYNAMAXX as Co-Founder: Full Alliance Group (OTC: "FAGI") Teams Up with Network Marketing Dynamo, Edgar Mojica, who will be Leading DYNAMAXX in its International Expansion, Product Reformulation and Relaunch
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.00–0.01
- Bid/Ask
- $0.01 / $0.01
- Market Cap
- $1.44 Mil
- Volume/Avg
- 2,325 / 80,065
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Full Alliance Group Inc provides nutraceutical and supplement products; extracorporeal blood oxygenation and ozonation treatments for patients. The company derives revenues from merchandise sales from physical locations and online channels.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- —
- Total Number of Employees
- —
Valuation
|
Metric
|
FAGI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FAGI
|
|---|---|
Quick Ratio | — |
Current Ratio | — |
Interest Coverage | — |
Quick Ratio
No chart available
Profitability
|
Metric
|
FAGI
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
No chart available
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Tcjcjkmbvn | Hvwvm | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Gsgphjdnm | Cfbzmw | $68.1 Bil | |
HLN
| Haleon PLC ADR | Tmjgzbrp | Kstsf | $36.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Jppczgw | Nwr | $14.3 Bil | |
VTRS
| Viatris Inc | Whkdlbbm | Nxc | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Phzcxcnsq | Bnv | $12.0 Bil | |
CTLT
| Catalent Inc | Bzlsyrz | Rkxmfv | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Bsfwllzt | Cmpct | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Fndxqfln | Zsr | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Ltsdxbzr | Gryvcx | $3.4 Bil |